Saudek Christopher D, Derr Rachel L, Kalyani Rita R
Division of Endocrinology and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Md, USA.
JAMA. 2006 Apr 12;295(14):1688-97. doi: 10.1001/jama.295.14.1688.
With the increasing prevalence of diabetes, successful management of blood glucose control is increasingly important. Current approaches to assessing glycemia include the use of self-monitoring of blood glucose (SMBG) and hemoglobin A1c (HbA1c).
To assess the evidence underlying the use of these 2 modalities, to evaluate confounders and sources of error in each test, to describe upcoming developments, and to reach evidence-based conclusions on their optimal use.
DATA SOURCES, STUDY SELECTION, AND DATA EXTRACTION: Reports identified from MEDLINE searches (1976-2005) using relevant terms were selected for quality and relevance to the stated questions. Particular attention was paid to larger cohort studies, clinical trials, meta-analyses, and established recommendations.
If used properly SMBG gives an acceptably accurate reflection of immediate plasma glucose levels. Study results vary, but in general, the evidence supports a positive effect of regular SMBG for improving glycemia, particularly in individuals treated with insulin. The best timing of SMBG and its frequency are controversial issues, but the clinical recommendation is for regular monitoring with frequency depending on the treatment and the instability of glycemia. In the relatively near term, SMBG could gradually be replaced by continuous glucose monitoring. HbA1c measures long-term glycemic control, reflecting a time-weighted mean over the previous 3 to 4 months. There are a number of physiologic and methodologic confounders that can affect HbA1c, but standardization of assays has been well established. The main value of HbA1c is its use as a predictor of diabetic complications and the proven effect of improved control of HbA1c on complication risk. A reasonable target value for HbA1c is less than 7%. A new method for measuring HbA1c may cause significant changes in the recommended levels, the numbers reported, and even the name of the test.
Assessing glycemia in diabetes can be a challenge, but approaches are available that promote successful management of blood glucose and may thereby lead to a significant reduction in morbidity and mortality related to diabetes.
随着糖尿病患病率的不断上升,成功控制血糖变得愈发重要。目前评估血糖水平的方法包括自我血糖监测(SMBG)和糖化血红蛋白(HbA1c)检测。
评估使用这两种方法的依据,评估每项检测中的混杂因素和误差来源,描述未来的发展趋势,并就其最佳使用得出基于证据的结论。
数据来源、研究选择与数据提取:从MEDLINE检索(1976 - 2005年)中使用相关术语识别出的报告,根据质量和与所提问题的相关性进行选择。特别关注大型队列研究、临床试验、荟萃分析和既定建议。
如果使用得当,自我血糖监测能对即时血浆葡萄糖水平给出可接受的准确反映。研究结果各异,但总体而言,证据支持定期自我血糖监测对改善血糖水平有积极作用,尤其是在接受胰岛素治疗的个体中。自我血糖监测的最佳时间和频率是有争议的问题,但临床建议是根据治疗情况和血糖不稳定程度进行定期监测。在相对近期内,自我血糖监测可能会逐渐被持续血糖监测所取代。糖化血红蛋白测量长期血糖控制情况,反映过去3至4个月的时间加权平均值。有许多生理和方法学上的混杂因素会影响糖化血红蛋白,但检测方法的标准化已得到很好的确立。糖化血红蛋白的主要价值在于其作为糖尿病并发症预测指标的用途,以及改善糖化血红蛋白控制对并发症风险的已证实效果。糖化血红蛋白的合理目标值应小于7%。一种新的糖化血红蛋白测量方法可能会导致推荐水平、报告数字甚至检测名称发生重大变化。
评估糖尿病患者的血糖水平可能具有挑战性,但现有方法有助于成功控制血糖,从而可能显著降低与糖尿病相关的发病率和死亡率。